Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study

European Urology

Volumn 68, Issue 1, 2015, Pages 147-153

  Caffo, Orazio ^a   De Giorgi, Ugo ^b   Fratino, Lucia ^c   Alesini, Daniele ^d   Zagonel, Vittorina ^e   Facchini, Gaetano ^f   Gasparro, Donatello ^g   Ortega, Cinzia ^h   Tucci, Marcello ⁱ   Verderame, Francesco ^j   Campadelli, Enrico ^k   Lo Re, Giovanni ^l   Procopio, Giuseppe ^m   Sabbatini, Roberto ⁿ   Donini, Maddalena ^o   Morelli, Franco ^p   Sartori, Donata ^k   Zucali, Paolo ^q   Carrozza, Francesco ^r   D'Angelo, Alessandro ^s   Vicario, Giovanni ^t   Massari, Francesco ^u   Santini, Daniele ^v   Sava, Teodoro ^w   Messina, Caterina ^x   Fornarini, Giuseppe ^y   La Torre, Leonardo ^k   Ricotta, Riccardo ^z   Aieta, Michele ^aa   Mucciarini, Claudia ^k   Zustovich, Fable ^e   Macrini, Sveva ^ab   Burgio, Salvatore Luca ^b   Santarossa, Sandra ^c   D'Aniello, Carmine ^f   Basso, Umberto ^e   Tarasconi, Sara ^g   Cortesi, Enrico ^d   Buttigliero, Consuelo ⁱ   Ruatta, Fiorella ^h   Veccia, Antonello ^a   Conteduca, Vincenza ^b   Maines, Francesca ^a   Galligioni, Enzo ^a   more..

^a SANTA CHIARA HOSPITAL   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g GENERAL HOSPITAL   (Italy)

^h CANDIOLO CANCER INSTITUTE   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^k General Hospital   (Italy)

^l S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^m NATIONAL CANCER INSTITUTE   (Italy)

ⁿ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^o GENERAL HOSPITAL   (Italy)

^p CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^q HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^r Medical Oncology Department General Hospital   (Italy)

^s San Vincenzo Hospital   (Italy)

^t San Giacomo Hospital   (Italy)

^u UNIVERSITY HOSPITAL OF VERONA   (Italy)

^v UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^w GENERAL HOSPITAL   (Italy)

^x PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^y UNIVERSITY OF GENOA   (Italy)

^z OSPEDALE NIGUARDA CA GRANDA   (Italy)

^aa Referral Cancer Center of Basilicata   (Italy)

^ab SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

Abiraterone acetate; Cabazitaxel; Cancer; Castration resistant prostate; Enzalutamide; Fourth line; Prognostic factors; Third line

Indexed keywords

ABIRATERONE ACETATE; ALKALINE PHOSPHATASE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; HEMOGLOBIN; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; ITALY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT FAILURE; TREATMENT OUTCOME;

ABIRATERONE ACETATE; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; ITALY; MALE; MULTIVARIATE ANALYSIS; PHENYLTHIOHYDANTOIN; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84942983803     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.10.014     Document Type: Article

References (26)

1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
2. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial. Lancet 2010;376:1147-54.
3. De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364: 1995-2005.
4. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367: 1187-97.
5. Bianchini D, Lorente D, Rodriguez-Vida A, et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castrationresistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 2014;50:78-84.
6. Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24:1807-12.
7. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24:1802-7.
8. Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014;65:30-6.
9. Schmid SC, Geith A, Boker A, et al. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer. Adv Ther 2014;31:234-41.
10. Badrising S, van der Noort V, van Oort IM, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014;120:968-75.
11. Thomsen FB, Roder MA, Rathenborg P, Brasso K, Borre M, Iversen P. Enzalutamide treatment in patients with metastatic castrationresistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol 2014;48:268-75.
12. Thomson D, Charnley N, Parikh O. Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer. Eur J Cancer 2014;50:1040-1.
13. Pezaro CJ, Omlin AG, Altavilla A, et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 2014;66:459-65.
14. Al Nakouzi N, Le Moulec S, Albigé s L, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015
15. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
17. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Statist Data Anal 1999;30:253-70.
18. Mandrekar J, Mandrekar S, Cha S. Cutpoint determination methods in survival analysis using SAS1. Presented at: SAS Users Group 28; March 30-April 2, 2003; Seattle, WA, USA.
19. Williams C, Mandrekar J, Mandrekar S, et al. Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes. Mayo Foundation Technical Report Series, No. 79. Rochester, MN: Department of Health Sciences Research, Mayo Clinic; 2006.
20. Efstathiou E, Titus M, Tsavachidou D, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2012;30:637-43.
21. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
22. Zhu ML, Horbinski CM, GarzottoM, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010;70:7992-8002.
23. Van Soest RJ, van Royen ME, de Morree ES, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamidemay affect drug sequence choices inmetastatic castrationresistant prostate cancer. Eur J Cancer 2013;49:3821-30.
24. Sartor AO, Oudard S, Ozguroglu M, et al. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial [abstract 4525]. J Clin Oncol 2011;29.
25. Chi KN, Scher HI, Molina A, et al. Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) [abstract 15]. J Clin Oncol 2012;30(Suppl 5).
26. Halabi S, Lin CY, Small EJ, et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst 2013;105: 1729-37.